Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

1. Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update

Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update | CADTH.ca Find the information you need Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines (...) – An Update Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update Last updated: June 28, 2019 Project Number: RC1142-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of repetitive transcranial magnetic stimulation for patients with treatment-resistant depression? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Bright Light Therapy for Depression: Clinical Effectiveness

Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness | CADTH.ca Find the information you need Bright Light Therapy for Depression: Clinical Effectiveness Bright Light Therapy for Depression: Clinical Effectiveness Last updated: August 28, 2019 Project Number: RB1391-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of bright (...) light therapy in patients with major depressive disorder or persistent depressive disorder? Key Message One systematic review, and two randomized controlled trials were identified regarding the clinical effectiveness of bright light therapy in patients with major depressive disorder or persistent depressive disorder. Files Rapid Response Summary of Abstracts Published : August 28, 2019 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Screening for depression

Screening for depression 1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-05 Screening for depression 1 Extract of final report S16-05 Version 1.0 Screening (...) for depression 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for depression Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2016 Internal Commission No.: S16-05 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

4. Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis

Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis | CADTH.ca Find the information you need Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis Last updated: June 11, 2019 Project Number: HE0022-000 Product Line: Technology Review Research Type: Drug Result type: Report (...) Expected Completion Date: October 28, 2019 Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Over the past decades, multiple classes of antidepressant drugs have been developed to treat this condition. The relative effectiveness and safety of antidepressants are uncertain. This project will review a recently published network meta-analysis featuring broad comparisons of several oral antidepressants for MDD. Implications for decision-making

2019 Publication 4890897

5. Esketamine for Treatment-Resistant Depression

Esketamine for Treatment-Resistant Depression Esketamine for Treatment-Resistant Depression | CADTH.ca CADTH Document Viewer Esketamine for Treatment-Resistant Depression Table of Contents Search this document Esketamine for Treatment-Resistant Depression April 2019 Summary Major depressive disorder (MDD) is a common, debilitating, and recurrent mental health disorder. Approximately 10% to 30% of patients with MDD will not reach complete clinical remission despite multiple antidepressant (...) pharmacologic approaches — this subpopulation is described as having treatment-resistant depression (TRD). TRD is a more challenging depressive disorder to treat and available therapies are often limited by significant psychological and physiological side effects. Esketamine is the S-enantiomer of racemic ketamine and is being developed as a nasal spray device for potential therapeutic use in patients with TRD. It has not yet been approved in any country but is under priority review at Health Canada

2019 CADTH - Issues in Emerging Health Technologies

6. Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment

Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment | CADTH.ca Find the information you need Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Internet-Delivered Cognitive Behavioural Therapy for Major (...) Depressive Disorder and Anxiety Disorders: A Health Technology Assessment Last updated: March 19, 2019 Project Number: OP0534-000 Product Line: Research Type: Device Result type: Report Major depressive disorder (MDD) is the occurrence of one or more major depressive episodes that last at least two weeks. Anxiety disorders include a range of conditions, including generalized anxiety disorder, panic disorder, and social anxiety disorder. MDD and anxiety disorders may be treated with pharmacological

2019 CADTH - Optimal Use

7. Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT

Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue

2019 NIHR HTA programme

8. Trial of SAGE-217 in Patients with Major Depressive Disorder. (PubMed)

Trial of SAGE-217 in Patients with Major Depressive Disorder. Altered neurotransmission of γ-aminobutyric acid (GABA) has been implicated in the pathogenesis of depression. Whether SAGE-217, an oral, positive allosteric modulator of GABA type A receptors, is effective and safe for the treatment of major depressive disorder is unknown.In this double-blind, phase 2 trial, we enrolled patients with major depression and randomly assigned them in a 1:1 ratio to receive 30 mg of SAGE-217 or placebo (...) once daily. The primary end point was the change from baseline to day 15 in the score on the 17-item Hamilton Depression Rating Scale (HAM-D; scores range from 0 to 52, with higher scores indicating more severe depression). Secondary efficacy end points, which were assessed on days 2 through 8 and on days 15, 21, 28, 35, and 42, included changes from baseline in scores on additional depression and anxiety scales, a reduction from baseline of more than 50% in the HAM-D score, a HAM-D score of 7

2019 NEJM

9. Psychological interventions in reducing stress, depression and anxiety among parents of children and adolescents with developmental disabilities: A systematic review and meta-analysis

Psychological interventions in reducing stress, depression and anxiety among parents of children and adolescents with developmental disabilities: A systematic review and meta-analysis To evaluate the effectiveness of psychological interventions in reducing stress, depression and anxiety among parents of children and adolescents with developmental disabilities.A systematic review and a meta-analysis.Seven electronic databases (CINAHL, CENTRAL, EMBASE, ProQuest Dissertation and Theses, PsycINFO (...) -analysis found that psychological interventions significantly reduced parental stress at postintervention but not at 3-6 months' postintervention. Inconclusive evidence was found for the effectiveness of psychological interventions in reducing parental depression and anxiety.Psychological interventions appeared to reduce parental stress temporarily. Healthcare professionals can offer varied psychological interventions for parents to choose from. Policymakers can ease accessibility and affordability

2019 EvidenceUpdates

10. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. (PubMed)

Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. Psychotic depression is a severely disabling and potentially lethal disorder. Little is known about the efficacy and tolerability of continuing antipsychotic medication for patients with psychotic depression in remission.To determine the clinical effects of continuing antipsychotic medication once an episode of psychotic depression has responded (...) to combination treatment with an antidepressant and antipsychotic agent.Thirty-six week randomized clinical trial conducted at 4 academic medical centers. Patients aged 18 years or older had an episode of psychotic depression acutely treated with sertraline plus olanzapine for up to 12 weeks and met criteria for remission of psychosis and remission or near-remission of depressive symptoms for 8 weeks before entering the clinical trial. The study was conducted from November 2011 to June 2017, and the final

2019 JAMA

11. A meta-analysis of randomized controlled trials of laughter and humour interventions on depression, anxiety and sleep quality in adults

A meta-analysis of randomized controlled trials of laughter and humour interventions on depression, anxiety and sleep quality in adults To quantify the effect of laughter and humour interventions on depression, anxiety, and sleep quality in adults.A meta-analysis of randomized controlled trials.PubMed, Embase, PsycINFO, Web of Science, Cochrane Central Register of Controlled Trials, Chinese National Knowledge Infrastructure, Weipu, and Wanfang Data were searched from their inception up (...) to December 2018.The reporting of this meta-analytical review was conducted according to the guidelines of the Cochrane Collaboration. Two reviewers selected the studies, extracted the data, and evaluated the risk of bias (Cochrane Collaboration bias assessment tool) of the included papers independently.Ten studies comprising 814 participants were included. Meta-analysis showed that these interventions significantly decreased adults' depression, anxiety, and improved their sleep quality. The results

2019 EvidenceUpdates

12. Effect of couple-based cognitive behavioural intervention on prevention of postnatal depression: multisite randomised controlled trial

Effect of couple-based cognitive behavioural intervention on prevention of postnatal depression: multisite randomised controlled trial To compare a couple-based cognitive behavioural intervention (CBI) for postnatal depression with CBI delivered to women alone and control (standard perinatal care).Multisite randomised controlled trial.Antenatal clinics at three regional public hospitals in Hong Kong.388 low-risk childbearing couples.Childbearing couples were randomly allocated to couple-based (...) CBI (n = 134), women-alone CBI (n = 124) or control (n = 130). The CBI consists of a 3-hour antenatal group session and two 30-minute postnatal telephone follow-up sessions.The primary outcome was depressive symptoms, measured on the Edinburgh Postnatal Depression Scale (EPDS). Assessments were collected at baseline (during pregnancy), 6 weeks, 6 months, and 12 months postpartum.Depressive symptoms were significantly more improved at 6 weeks postpartum for mothers in couple-based CBI than in women

2019 EvidenceUpdates

13. Non-traditional support workers delivering a brief psychosocial intervention for older people with anxiety and depression: the NOTEPAD feasibility study

Non-traditional support workers delivering a brief psychosocial intervention for older people with anxiety and depression: the NOTEPAD feasibility study Non-traditional support workers delivering a brief psychosocial intervention for older people with anxiety and depression: the NOTEPAD feasibility study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Third sector support workers can deliver a psychosocial intervention to older people with anxiety and depression, and it was feasible to recruit patients, but further development of recruitment strategies is needed. {{author}} {{($index , , , , , , , , , , & . Heather Burroughs 1 , Bernadette Bartlam 1 , Peter

2019 NIHR HTA programme

14. Effect of Pulmonary Rehabilitation on Symptoms of Anxiety and Depression in COPD: A Systematic Review and Meta-Analysis

Effect of Pulmonary Rehabilitation on Symptoms of Anxiety and Depression in COPD: A Systematic Review and Meta-Analysis Pulmonary rehabilitation (PR) improves exercise capacity and quality of life in people with COPD; however, its effect on anxiety and depression symptoms is less clear. Existing data are difficult to apply to clinical PR because of diverse interventions and comparators. This review evaluated the effectiveness of PR on anxiety and depression symptoms in people with COPD.A (...) systematic review and meta-analysis (PROSPERO CRD42018094172) was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines on randomized controlled trials comparing PR (≥ 4 weeks' duration) with usual care. Four electronic databases were searched to February 2018 using terms related to COPD, PR, anxiety, and depression. Data were extracted by two assessors using standardized templates. Study quality was appraised via the PEDro scale, and evidence was rated

2019 EvidenceUpdates

15. Efficacy of a transdiagnostic emotion-focused exposure treatment for chronic pain patients with comorbid anxiety and depression: a randomized controlled trial

Efficacy of a transdiagnostic emotion-focused exposure treatment for chronic pain patients with comorbid anxiety and depression: a randomized controlled trial The comorbidity between chronic pain and emotional problems has proven difficult to address with current treatment options. This study addresses the efficacy of a transdiagnostic emotion-focused exposure treatment ("hybrid") for chronic pain patients with comorbid emotional problems. Adults (n = 115) with chronic musculoskeletal pain (...) ) and pain interference (d = 0.63) and significantly better follow-up outcomes on depression (d = 0.43) and pain interference (d = 0.51). There were no differences on anxiety and pain intensity. Observed proportions of clinically significant improvement favoured the hybrid on all but one comparison, but no statistically significant differences were observed. We conclude that the hybrid emotion-focused treatment may be considered an acceptable, credible, and efficacious treatment option for chronic pain

2019 EvidenceUpdates

16. Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis

Beyond pain: can antidepressants improve depressive symptoms and quality of life in patients with neuropathic pain? A systematic review and meta-analysis Neuropathic pain can be a predictor of severe emotional distress, up to full-blown depressive states. In these patients, it is important to move beyond the sole treatment of pain, to recognize depressive symptoms, and to ultimately improve the quality of life. We systematically searched for published and unpublished clinical trials assessing (...) the efficacy and tolerability of antidepressants vs placebo on depression, anxiety and quality of life in patients with neuropathic pain, and pooled data in a meta-analysis. A total of 37 studies fulfilled eligibility criteria and 32 provided data for meta-analysis. Antidepressants were more effective than placebo in improving depressive symptoms (standardized mean difference -0.11; 95% confidence interval -0.20 to -0.02), although the magnitude of effect was small, with a number needed to treat of 24

2019 EvidenceUpdates

17. Depression in children and young people: identification and management

Depression in children and young people: identification and management Depression in children and y Depression in children and young people: oung people: identification and management identification and management NICE guideline Published: 25 June 2019 www.nice.org.uk/guidance/ng134 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline (...) inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Depression in children and young people: identification and management (NG134) © NICE 2019. All rights reserved. Subject to Notice of rights (https

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

18. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus (...) a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray.This was a phase 3, double-blind, active-controlled, multicenter study conducted at 39 outpatient referral centers. The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively. Confirmed nonresponders were randomly assigned to treatment

2019 EvidenceUpdates

19. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established.To assess the efficacy of esketamine nasal spray plus an oral antidepressant compared with an oral antidepressant plus placebo nasal spray in delaying relapse of depressive

Full Text available with Trip Pro

2019 EvidenceUpdates

20. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults To assess adverse effects of pharmacologic antidepressants for treatment of major depressive disorder (MDD) in adults 65 years of age or older.Systematic review and meta-analysis.Specialist or generalist outpatient setting, rehabilitation facility, and nursing facilities.Persons 65 years and older with MDD.Selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs

2019 EvidenceUpdates